TLR9 and Huntington disease: To confirm the capacity of thalidomide to inhibit the IFN-I pathway, PBMCs isolated from HD were stimulated for 24 h with CpG-A 2216, a TLR9 agonist, or M. leprae whole cell sonicate in the presence or not of thalidomide.